Veerhealth Care is currently trading at Rs. 23.85, up by 0.85 points or 3.70% from its previous closing of Rs. 23.00 on the BSE.
The scrip opened at Rs. 23.00 and has touched a high and low of Rs. 24.00 and Rs. 23.00 respectively. So far 23569 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 30.10 on 23-Feb-2024 and a 52 week low of Rs. 13.60 on 13-Dec-2023.
Last one week high and low of the scrip stood at Rs. 24.98 and Rs. 22.51 respectively. The current market cap of the company is Rs. 46.42 crore.
The promoters holding in the company stood at 30.41%, while Non-Institutions held 69.59% in the company.
Veerhealth Care has purchased 27,451 Sq. Ft. of additional land adjacent to its current manufacturing facility in Vapi, Gujarat. This acquisition will enable the establishment of new manufacturing lines which will be as per CGMP norms as required by USFDA to meet the increasing demand from the US market.
Following the expansion, the total plot area will be 58,623 sq. ft., combining the existing 31,172 sq. ft. with the newly acquired 27,451 sq. ft. The total constructed area will rise to 90,000 sq. ft., with 60,000 sq. ft. from the current facility and 30,000 sq. ft. from the new construction. The company expects a substantial increase in demand & positive feedback from the US, East & North African market after the initial supply of oral care products. To address this anticipated demand, Veerhealth Care will introduce high-capacity manufacturing and filling lines in the new facility.
The new facility will be additionally equipped with plastic blow molding and injection molding machines, allowing for backward integration by producing packing materials internally. This strategic move aims to provide a comprehensive solution to client requirements and is projected to help Veerhealth Care achieve a revenue target of Rs 100 crore over the next 2 to 3 years with a 10% PAT Margin. All manufacturing stages of the company's products will be completed within its own facilities.
Veerhealth Care is engaged mainly in business of trading and manufacturing and marketing research based ayurvedic medicines.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
